Vivan Therapeutics
1 known investors
Vivan offers a genomics-based drug screening service (TuMatch) that analyzes a tumor's genetic and molecular profile to identify personalized drug combinations, including non-cancer and investigational drugs, for individual cancer patients. Developed with Mount Sinai's Icahn School of Medicine, it focuses on colorectal, lung, pancreatic, and other gastrointestinal cancers.
BiotechDigital HealthHealthtech
Investors · 1
In the news
Frequently asked questions
- What does Vivan Therapeutics do?
- Vivan offers a genomics-based drug screening service (TuMatch) that analyzes a tumor's genetic and molecular profile to identify personalized drug combinations, including non-cancer and investigational drugs, for individual cancer patients. Developed with Mount Sinai's Icahn School of Medicine, it focuses on colorectal, lung, pancreatic, and other gastrointestinal cancers.
- Who are Vivan Therapeutics's investors?
- Vivan Therapeutics's investors include Granatus Ventures.